Halozyme Therapeutics Profit Margin

Halozyme Therapeutics (HALO) currently reports a profit margin of 24.86% as of June 2026. That compares with 47.28% in the prior-year period — down 47.4% year over year. That is above the Healthcare sector average of 13.89%. Use the charts on this page to explore Halozyme Therapeutics's profit margin history and peer comparisons.

Halozyme Therapeutics's profit margin decreased from 47.28% to 24.86% — a 47.4% year-over-year decrease (period ending June 2026). Watching multi-year history on the chart below helps separate one-off swings from a lasting trend.

Halozyme Therapeutics's profit margin of 24.86% is higher than the Healthcare sector average of 13.89%. That is roughly 78.9% above the sector mean. A reading higher peers can reflect different growth expectations, capital structure, or profitability — so it is worth checking the peer comparison chart before drawing conclusions.

There is no universal 'good' profit margin, but Halozyme Therapeutics's current 24.86% should be judged against Healthcare norms (sector average: 13.89%) and against HALO's own history. Strong, stable readings often indicate durable competitive advantage; volatile or declining ones deserve a closer look at margins and capital efficiency.

Start with the current profit margin of 24.86%, then check the historical chart for trend and the peer comparison chart for relative positioning. The Healthcare average is 13.89%. From there, open related valuation or income-statement pages for Halozyme Therapeutics, and consider following HALO for alerts when major investors trade the stock.